home / stock / pmcb / pmcb news

PMCB News and Press, PharmaCyte Biotech Inc. From 09/02/20

Stock Information
Company Name: PharmaCyte Biotech Inc.
Stock Symbol: PMCB
Market: OTC
Website: pharmacyte.com
Menu
PMCB PMCB Quote PMCB Short PMCB News PMCB Articles PMCB Message Board
Get PMCB Alerts

News, Short Squeeze, Breakout and More Instantly...
PMCB - PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has submitted an Investigational New Drug appl...
PMCB - PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it has appointed José L. Iglesias M.D. as Consulti...

PMCB - FDA Formally Accepts PharmaCyte Biotech's Drug Master File for Company's Pancreatic Cancer Therapy

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that the Drug Master File (DMF) that its partner, Austrianova, filed ...

PMCB - PharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic Cancer

NEW YORK, NY, Aug. 03, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached what can only be described as a momentous milestone in its history and what should be considered a remarkable moment for any small biotech—the submission of an Investigational New Drug Applic...
PMCB - PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that the COVID-19 Molecular tests it has licensed from Hai Kang Life ...

PMCB - PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company's Pancreatic Cancer Therapy

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that its partner, Austrianova, has submitted a Drug Master File (DMF)...

PMCB - PharmaCyte Biotech Successfully Completes Container Closure Integrity Test

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the Container Closure Integrity (C...
PMCB - PharmaCyte Biotech Successfully Completes Three-Month Stability Study

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the three-month product stability ...

PMCB - PharmaCyte Biotech's COVID-19 Test Offers "Pool Testing" Dr. Fauci and White House Coronavirus Task Force Now Considering

NEW YORK, NY, June 29, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) may have what the White House Coronavirus Task Force is looking for just as COVID-19 cases are surging across the country.  Last week, Dr. Anthony Fauci, director of the National Institute of Allergy and I...

PMCB - PharmaCyte Biotech Provides IND Submission Update for Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it is closing the gap in completing its Investigational New Drug...
Previous 10 Next 10